Seroprevalance of HBsAg, anti-HIV 1&2 and anti-HCV by chemiluminescence method - A hospital based study from 2007 to 2014

• Main Authors: Anil Kumar, Madhavi Latha, Sukrutha Gopal, Vanaja, Imtiyaz Ahmed, Radhika Chowdary
• Format: Article
• Language: English
• Published: KIMS Foundation and Research Center 2015-01-01
• Series: Journal of Medical and Scientific Research
• Subjects: Seroprevalence of HBsAg; anti-HIV 1&2; anti-HCV; chemiluminescence method
• Online Access: http://jmsronline.com/article.aspx?ID=Seroprevalance-of-HBsAg-anti-HIV-1-and-2-and-anti-HCV-by-chemiluminescence-method
• ISSN: 2321-1326; 2394-112X

Introduction: Hepatitis B virus (HBV), human immunodeficiency virus 1&2 (HIV1&2) and hepatitis C virus (HCV) are major public health problem. Detection of hepatitis B surface antigen (HBsAg), antibodies to human immunodeficiency virus 1&2 and hepatitis C virus in patients (both inpatients and outpatients) can help in patient management. Screening of patient samples for HBsAg, anti-HIV 1&2 and anti-HCV is important in managing surgical and medical care. The objective is to know prevalence of hepatitis B surface antigen (HBsAg), antibodies to HIV 1&2 and HCV inpatient and outpatient, their gender, age wise distribution and department wise distribution. Material & methods: The present study was conducted in the Department of Microbiology, Krishna Institute of Medical Sciences (KIMS), Secunderabad, Telangana, during a study period of 8 years from January 2007 to December 2014. It is a cross sectional study. It is a laboratory based study, no clinical correlation has been done. The positive/reactive samples were studied for their gender, age group and department. Analysis was done on a yearly basis. A cumulative data of 8 years is being presented. The samples were screened by enhanced chemiluminescence (ECLIA) technology by using an instrument, Vitros ECiQ(Ortho Clinical Diagnostic). Results: 1,00,590 patients were screened 1,805 (1.79 %) were positive for HBsAg. 92,819 patients screened 501(0.53%) were reactive for HIV 1&2 antibodies. 61,072 screened 744(1.21%) were reactive for HCV infection. The seroprevalence of all viral markers is more in males than females. In the present study seropositivity of HBsAg was higher in 41-50 year & 51-60 years followed by 31-40 years & 61-70 years. Highest prevalence of HIV was observed in 31-40 years followed by 41-50 years. Seropositivity of HCV was higher in 51-60 years followed by 41-50 years & 61-70 years. Conclusion: Emphasizes the need of screening of viral markers for inpatients and out patients. Adherence to universal precautions.